{
  "id": 1769622318752,
  "seqId": 168,
  "title": "Inherited Retinal Disorders: The RP & CSNB Master Guide",
  "summary": "An exhaustive clinical reference detailing Retinitis Pigmentosa, Leber Congenital Amaurosis, Congenital Stationary Night Blindness, and Cone Dysfunction Syndromes, encompassing genetics, diagnostic investigations, and emerging therapies.",
  "date": "2026-01-28T17:45:18.752Z",
  "data": {
    "title": "Inherited Retinal Disorders: The RP & CSNB Master Guide",
    "summary": "An exhaustive clinical reference detailing Retinitis Pigmentosa, Leber Congenital Amaurosis, Congenital Stationary Night Blindness, and Cone Dysfunction Syndromes, encompassing genetics, diagnostic investigations, and emerging therapies.",
    "summary_illustration": "<svg viewBox=\"0 0 100 100\" xmlns=\"http://www.w3.org/2000/svg\"><circle cx=\"50\" cy=\"50\" r=\"40\" fill=\"none\" stroke=\"hsl(215, 90%, 45%)\" stroke-width=\"2\"/><path d=\"M30 50 Q50 20 70 50 Q50 80 30 50\" fill=\"none\" stroke=\"hsl(215, 90%, 45%)\" stroke-width=\"2\"/><circle cx=\"50\" cy=\"50\" r=\"8\" fill=\"hsl(215, 90%, 45%)\"/><path d=\"M20 20 L25 25 M80 20 L75 25 M20 80 L25 75 M80 80 L75 75\" stroke=\"hsl(215, 90%, 45%)\" stroke-width=\"2\"/></svg>",
    "sections": [
      {
        "title": "Retinitis Pigmentosa (RP) Overview",
        "icon": "visibility",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "Retinitis Pigmentosa (1)",
          "branches": [
            "Commonest inherited retinal disorder",
            "Affects 1 in 3–4,000 of population",
            "Progressive dysfunction, cell loss, and atrophy of retinal tissue",
            "Initial effect: Photoreceptors (rods first, then cones in later stages)",
            "Subsequent atrophy of other retinal layers",
            "NFL preserved till late (exploited in retinal implant technology)"
          ]
        }
      },
      {
        "title": "RP Inheritance & Genetics",
        "icon": "dna",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "purple",
        "content": "The relative frequency of the different modes of inheritance differs widely in different series, but 750% of patients have no family history of RP. AD RP is often of later onset and less severe, whereas XL and AR disease is associated with an earlier onset and is more severe. Mutations in over 150 genes have been identified in RP to date (see Table 13.16)."
      },
      {
        "title": "Systemic Distribution & Syndromes",
        "icon": "account_tree",
        "type": "chart",
        "layout": "half_width",
        "color_theme": "green",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "Isolated RP (No systemic features)",
              "value": 75
            },
            {
              "label": "Associated Systemic Disease (usually AR)",
              "value": 25
            }
          ]
        }
      },
      {
        "title": "Clinical Features of RP",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Nyctalopia, tunnel vision, dVA (later in the disease process).",
          "Mid-peripheral ‘bone spicule’ retinal pigmentation.",
          "Waxy pallor of the optic disc, arteriolar attenuation.",
          "Ocular associations: cataract (esp. posterior subcapsular); myopia (especially in XL RP).",
          "Systemic associations: RP can be syndromic (see systemic associations in Table 13.17).",
          "Complications: CMO, ERM, Coats’-like vasculopathy."
        ]
      },
      {
        "title": "Diagnostic Investigations",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "ERG: scotopic affected to a greater extent than photopic; used to monitor disease.",
          "EOG: abnormal—proportional to the ERG.",
          "VF: recording progressive constriction of VF with kinetic testing is a reliable measure of change over time.",
          "OCT: loss of outer retinal structures, particularly the ellipsoid zone and ONL.",
          "FAF: a ring of hyperfluorescence often demarcates regions of affected and unaffected retina. Reduced autofluorescence in areas of cell death."
        ]
      },
      {
        "title": "RP Variants & Patterns",
        "icon": "category",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "purple",
        "content": "RP variants include unusual distributions (sectoral or pericentral RP) and characteristic patterns such as retinitis punctata albescens (scattered white dots predating more typical RP changes) and enhanced S-cone syndrome (white, hyperautofluorescent dots around the arcades that evolve to nummular pigmentary patches, macular schisis). R ETINITIS PI g MENTOSA (1) 637"
      },
      {
        "title": "Differential Diagnosis",
        "icon": "difference",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Retinal inflammatory diseases (e.g. rubella, syphilis, infectious retinitis)",
          "Autoimmune and paraneoplastic retinopathies",
          "Drug toxicity (e.g. chloroquine)",
          "Pigmented paravenous chorioretinal atrophy",
          "Vitamin A deficiency",
          "Traumatic retinopathy",
          "Long-standing retinal detachment",
          "Diffuse Unilateral Subacute Neuroretinitis (DUSN) - previously attributed to ‘unilateral’ RP"
        ]
      },
      {
        "title": "Supportive & Medical Treatment",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Supportive: genetic/psychological/emotional counselling, visual impairment registration, refractive error management, low vision aids, mobility training/social services.",
          "Macular oedema: Carbonic anhydrase inhibitors; consider topical dorzolamide or brinzolamide initially; oral acetazolamide if no improvement (monitor renal function).",
          "Nutritional supplements: Role controversial; Vitamin A palmitate no longer recommended; DHA (1200mg/d) and lutein (12mg/d) may be worth considering (limited evidence base).",
          "Valproic acid: No benefit."
        ]
      },
      {
        "title": "Cataract Surgery Precautions in RP",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Reduce operating light levels",
          "Avoid small capsulorhexis (higher rate of phimosis)",
          "Meticulous clearance of lens epithelial cells from posterior capsule (higher rate of PCO)",
          "Slow taper of postoperative topical NSAIDs and steroids (higher rate of CMO)"
        ]
      },
      {
        "title": "Future Therapies",
        "icon": "rocket_launch",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Gene and stem cell therapies: phase I/II trials under way for LCA, Usher’s, Stargardt’s, and some achromatopsia.",
          "Argus II epiretinal prosthesis system: recently licensed in Europe for advanced RP. 836 638 C HAPTER 13 Medical retina"
        ]
      },
      {
        "title": "Leber Congenital Amaurosis (LCA)",
        "icon": "child_care",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Mutations in >25 genes.",
          "Congenital blindness, nystagmus, often hypermetropia.",
          "Extinguished ERG responses.",
          "Pupillary light reflexes: absent or diminished.",
          "Systemic associations: uncommon; associated with oculodigital syndrome and keratoconus.",
          "Early Fundus: normal appearance or subtle RPE changes/vessel attenuation.",
          "Characteristic phenotypes: RPE65, RDH12, and CRB1-associated LCA."
        ]
      },
      {
        "title": "Bietti’s Crystalline Dystrophy",
        "icon": "diamond",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Rare AR chorioretinal dystrophy with intraretinal crystalline deposits.",
          "Common in East Asia (Japan and China).",
          "Gene: Mutations in CYP4V2 (disordered lipid metabolism).",
          "Presentation: Routine evaluation, night blindness, or peripheral VF constriction.",
          "Pathology: Degeneration in RPE and choriocapillaris.",
          "FFA: Typical ‘moth-eaten’ appearance.",
          "Cornea: Perilimbal subepithelial corneal deposits.",
          "Progression: Diminution of ERG, VF constriction, dVA; legal blindness by 5th/6th decade. R ETINITIS PI g MENTOSA (2) 639"
        ]
      },
      {
        "title": "Table 13.16: Genes Involved in RP (Selected)",
        "icon": "list_alt",
        "type": "table",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "AD RP*",
            "AR RP†",
            "XL RP",
            "Digenic RP"
          ],
          "rows": [
            [
              "Rhodopsin ^ (e.g. p.Pro23His, Pro347Leu)",
              "USH2A (assoc. with Usher 2)",
              "RPGR",
              "Mutation in PRPH2 and ROM1"
            ],
            [
              "RP1^",
              "EYS",
              "RP2",
              ""
            ],
            [
              "PRPF31, PRPF8, PRPF6, SNRNP200",
              "PDE6B, PDE6A, CNGA1",
              "",
              ""
            ],
            [
              "PRPH2 (e.g. p.Arg172Trp)",
              "MERTK, RLBP1, TULP1",
              "",
              ""
            ],
            [
              "NRL^",
              "RPE65, CRB1, RDH12, CEP290",
              "",
              ""
            ]
          ]
        }
      },
      {
        "title": "Genetic Context Footnotes",
        "icon": "info",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": "* Mutations in >20 genes identified, 760–70% of AD RP patients; RHO is commonest cause. † Mutations in >30 genes identified, 74050% of AR RP patients; commonest is USH2A (10–15% of AR RP). ^ Rarely bi-allelic mutations cause recessive disease."
      },
      {
        "title": "Table 13.17: Associations of RP (Selected)",
        "icon": "group_work",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Isolated",
            "Systemic"
          ],
          "rows": [
            [
              "Sporadic",
              "Usher syndrome"
            ],
            [
              "Familial (AD, AR, XL, mitochondrial)",
              "BBS (Bardet-Biedl syndrome)"
            ],
            [
              "",
              "Laurence–Moon syndrome"
            ],
            [
              "",
              "Kearns–Sayre syndrome"
            ],
            [
              "",
              "Mucopolysaccharidoses I–III"
            ],
            [
              "",
              "Abetalipoproteinaemia"
            ],
            [
              "",
              "Refsum’s disease 046 640"
            ]
          ]
        }
      },
      {
        "title": "Congenital Stationary Night Blindness (CSNB)",
        "icon": "nights_stay",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "center": "CSNB",
          "branches": [
            "Early non-progressive nyctalopia",
            "Variable dVA, refractive error (myopia/hyperopia)",
            "Nystagmus and strabismus",
            "Normal Fundus vs Abnormal Fundus subtypes",
            "Abnormal fundus types may be progressive"
          ]
        }
      },
      {
        "title": "CSNB Classification (Normal Fundus)",
        "icon": "grid_view",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "• AD CSNB: Defect at rod phototransduction cascade (Riggs type). • AR and XL CSNB: Defect in signal transmission from photoreceptors to bipolar cells (Schubert–Bornschein type). • cCSNB (Complete): Mutations in NYX, GRM6, TRPM1; ON pathway defects. • iCSNB (Incomplete): Mutations in CACNA1F, CABP4, CACNA2D4; ON and OFF pathway defects. • AD CSNB Genes: RHO, GNAT1, PDE6B."
      },
      {
        "title": "CSNB Diagnostic Investigations",
        "icon": "query_stats",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "cCSNB: No detectable rod-specific ERG; electronegative bright flash response (reduced b-to-a wave ratio); subtle cone ERG abnormalities (ON bipolar dysfunction).",
          "iCSNB: Detectable rod-specific ERG; negative bright flash response; marked cone ERG abnormalities (ON and OFF pathway involvement).",
          "AD CSNB: Inner retinal rod dysfunction on ERG with normal cone ERGs; or attenuated rod responses with standard bright flash response lacking negative waveform."
        ]
      },
      {
        "title": "Differential Diagnosis: Nyctalopia",
        "icon": "search",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Vitamin A deficiency (grey-white fundus spots)",
          "RP (peripheral pigmentation)",
          "Choroideraemia (choroidal atrophy)",
          "Autoimmune/paraneoplastic retinopathies"
        ]
      },
      {
        "title": "CSNB with Abnormal Fundi",
        "icon": "visibility_off",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": "Oguchi’s Disease: AR CSNB, golden yellow metallic sheen, Mizuo phenomenon (normalizes after dark adaptation). OCT: IS-OS junction visible only after dark adaptation. Genes: SAG, GRK1. Fundus albipunctatus: Rare AR CSNB; tiny white dots/flecks sparing macula (retinoid accumulation). Genes: RDH5 (commonest), RLBP1, RPE65 (last two cause progressive disease). 246 642"
      },
      {
        "title": "Inherited Disorders of Cone Function",
        "icon": "palette",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "center": "Cone Function Disorders",
          "branches": [
            "Non-progressive (Cone dysfunction syndromes, early onset)",
            "Progressive (Cone dystrophies, later onset)",
            "Achromatopsia (rod monochromatism)",
            "Blue cone monochromatism",
            "Progressive cone-rod dystrophies"
          ]
        }
      },
      {
        "title": "Achromatopsia (Rod Monochromatism)",
        "icon": "brightness_medium",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Prevalence: 1 in 30,000; AR disorder.",
          "Clinical: Poor VA (6/36–6/60), absent colour vision, pendular nystagmus, marked photophobia from birth.",
          "Forms: Complete or incomplete (residual colour vision, better VA 6/24–6/36).",
          "Fundus: Normal or mild RPE changes.",
          "ERG: Non-recordable cone responses, normal rod responses (essential to differentiate from LCA).",
          "OCT: Normal fovea to hyporeflective optically empty cavity; foveal hypoplasia.",
          "Treatment: Gene therapy trials (CNGB3, CNGA3) under way in UK/Germany."
        ]
      },
      {
        "title": "Blue Cone Monochromatism & Progressive Cone Dystrophies",
        "icon": "trending_down",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Blue Cone Monochromatism: XL disorder, 1 in 100,000; high myopia; absent L/M-cone, normal S-cone/rod function. Preservation of tritan function.",
          "Progressive Cone Dystrophies: Heterogeneous; 2nd/3rd decade onset; symptoms: dVA, colour loss, photophobia.",
          "Progression: Rod involvement leads to nyctalopia and VF defects.",
          "Fundus: Mild RPE changes to Bull’s eye maculopathy or advanced RP appearance.",
          "Syndromes: Associated with spinocerebellar ataxia, BBS, or Alstrom syndrome.",
          "ERG: Generalized dysfunction; cone system > rod system; early macular involvement."
        ]
      }
    ],
    "chapterId": "orbit"
  },
  "chapterId": "orbit",
  "_newlyImported": 1769622318752,
  "communityId": "sub_1769618268159_2xxn2eoynv6crn",
  "communityAuthor": "Dodiii",
  "communityDate": "2026-01-28T16:37:48.159Z"
}